Perspectives About Modulating Host Immune System in Targeting SARS-CoV-2 in India

Sreyashi Majumdar¹, Rohit Verma², Avishhek Saha³, Parthasarathi Bhattacharyya⁴, Pradipta Maji⁵, Milan Surjit², Manikuntala Kundu⁶, Joyoti Basu⁶ and Sudipto Saha*¹

¹ Division of Bioinformatics, Bose Institute, Kolkata, India, ² Virology Laboratory, Vaccine and Infectious Disease Research Centre, Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, India, ³ Ubiquitous Analytical Techniques, CSIR-Central Scientific Instruments Organisation, Chandigarh, India, ⁴ Department of Respiratory Medicine, Institute of Pulmocare and Research, Kolkata, India, ⁵ Biomedical Imaging and Bioinformatics Lab, Machine Intelligence Unit, Indian Statistical Institute, Kolkata, India, ⁶ Department of Chemistry, Bose Institute, Kolkata, India

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus induced disease-2019 (COVID-19), is a type of common cold virus responsible for a global pandemic which requires immediate measures for its containment. India has the world’s largest population aged between 10 and 40 years. At the same time, India has a large number of individuals with diabetes, hypertension and kidney diseases, who are at a high risk of developing COVID-19. A vaccine against the SARS-CoV-2, may offer immediate protection from the causative agent of COVID-19, however, the protective memory may be short-lived. Even if vaccination is broadly successful in the world, India has a large and diverse population with over one-third being below the poverty line. Therefore, the success of a vaccine, even when one becomes available, is uncertain, making it necessary to focus on alternate approaches of tackling the disease. In this review, we discuss the differences in COVID-19 death/infection ratio between urban and rural India; and the probable role of the immune system, co-morbidities and associated nutritional status in dictating the death rate of COVID-19 patients in rural and urban India. Also, we focus on strategies for developing masks, vaccines, diagnostics and the role of drugs targeting host-virus protein-protein interactions in enhancing host immunity. We also discuss India’s strengths including the resources of medicinal plants, good food habits and the role of information technology in combating COVID-19. We focus on the Government of India’s measures and strategies for creating awareness in the containment of COVID-19 infection across the country.

Keywords: SARS-CoV-2, genetic variations, host immuno-modulation, repurposed drugs, vaccines, medicinal plants, CT scans, artificial intelligence
INTRODUCTION

Coronavirus disease 2019 (COVID-19) outbreak, caused by the novel coronavirus (SARS-CoV-2) has emerged as a global epidemic and posed serious worldwide public health concerns owing to the contagious nature of the virus and high death rate. Transmission through droplets facilitated its rapid spread and caused panic across the globe. There were 80,776,890 confirmed cases worldwide till December 30, 2020. India has also been largely affected by instances of COVID-19. SARS-CoV-2 viral protein interacts with various host proteins to mediate viral entry and replication in the human host (Khorsand et al., 2020). Targeting virus and host protein-protein interactions or downstream signaling cascades using novel or repositioned drugs, serves as one of the strategies for COVID-19 therapy. Several drugs such as remdesivir, dexamethasone, hydroxychloroquine, ivermectin, azithromycin, tocilizumab, famotidine, thalidomide have been evaluated in different countries for their efficacy in treating COVID-19 (Omolo et al., 2020). Convalescent plasma therapy has been recommended by FDA as an alternative therapeutic strategy for severe forms of COVID-19 infection. Vaccination has been considered as the major option for containing the COVID-19 pandemic. Presently, 172 vaccine candidates are in developmental stage, while 63 have entered clinical trials. The Oxford COVID-19 group have clinically proven the safety of the ChAdOx1 nCoV-19 vaccine in triggering humoral and cellular immune response against SARS-CoV-2. The vaccine is presently under the phase 3 trial program across the world (Folegatti et al., 2020). The phase 3 trials of Covishield, the Oxford vaccine in India have been conducted under the supervision of Serum Institute of India, Pune and the vaccine has been approved for emergency supply and use in India. COVAXIN has been developed as India’s first indigenous vaccine by Bharat Biotech in association with Indian Council of Medical Research (ICMR). COVAXIN has currently gone into Phase III clinical trial after successful completion of Phase I and II clinical trials started by Bharat Biotech from July, 2020 onwards. Recently, the Drug Controller General of India (DCGI) has granted emergency approval to COVAXIN in India. The Ministry of Ayush under the Govt. of India has emphasized the importance of exploiting medicinal herbs in the context of COVID-19. Indigenous medicinal plants with immune regulating properties have often served to boost immunity and render protection against
Majumdar et al. Modulating Host Immunity in COVID-19

FIGURE 1 | Schematic representation of the possible strategies for modulating the host immune system in order to control SARS-CoV-2 infection.

and Indian herbs and plants with medicinal and immuno-modulating properties. Lastly, it deals with role of AI and various Government strategies adopted in India for addressing the COVID-19 pandemic.

GENERAL SCENARIO IN INDIA

COVID-19 Infection and Death Rate in States and Union territories (UTs) of India: Association With Lifestyle Habits, Proximity to Airport and Urbanization

The first case of COVID-19 in India was diagnosed in March, 2020. From that time onwards, there has been rise in the incidence of COVID-19 in India with 2,871 and 101,077 active cases on April 3, 2020 and June 2, 2020 respectively. The number of active cases reached a peak of 1,018,454 on September 17, 2020 followed by a decrease to 528,428 active cases on November 4, 2020 and 258,747 active cases on December 30, 2020 and (as evident from Figure 2A). Till December 30, 2020, there has been a total of 10,267,283 confirmed cases in India with a total of 148,774 deaths8. In terms of total number of cases, India occupies the second position after United States and is followed by developed nations such as Brazil, Russia, France, and the United Kingdom (as shown in Supplementary Table 1). The numbers of daily new cases have reduced considerably in December, 2020 as compared to that in September, 2020. There has been a consistent increase in percent recovery from April to December with a minimum recovery rate of 69.06% in April 3, 2020 to a recovery rate of 98.51% on December 30, 2020 (as shown in Figure 2B). Likewise, the death percentage has declined to 1.49% on December 30, 2020 after a surge of 30.94% in April 3, 2020 (see text footnote 71). The decrease in COVID-19 deaths (in terms of death/total confirmed case ratio) across different states of India from June, 2020 to December, 2020 has been tabulated in Supplementary Table 2.

States and cities of India harboring busy international airports (such as Kolkata in West Bengal; Ahmedabad, Surat in Gujrat; Mumbai in Maharashtra; New Delhi in Delhi and Chennai 8https://Www.Worldometers.Info/Coronavirus/Country/India/
in Tamil Nadu) have shown high COVID-19 death rates. The total number of confirmed cases and death rates in Indian cities with important international airports has been tabulated in Supplementary Table 3.

The incidences of COVID-19, death/total cases ratio and death rate have been higher in urban India than in rural areas. The death rate in urban India showed a decline in November, 2020 but, there is no significant change in the rural COVID-19 death rate (as evident from Figure 3, Table 1 and Supplementary Table 4). Early COVID-19 cases in India were primarily diagnosed in cities. Subsequent to the movement of migrant laborers from urban to rural areas and easing of transportation between rural and urban areas, there has been an increase in COVID-19 cases in rural India. High population density, greater economic activity, infrastructure development and movement of people contribute to constraints in social distancing in urban areas. Urban food habits (fast food, alcohol consumption), lifestyle patterns (improper sleep pattern, lack of physical exercise, stress) and high levels of pollution result in non-communicable lifestyle diseases (such as obesity, diabetes, and hypertension), which create additional complications in COVID-19 patients. Instances of such disorders are lower among rural population. Besides, rural lifestyle practices such as consumption of hot food, prolonged periods of sun exposure due to agricultural field work, lesser crowding, limited instances of handshaking may prove to be advantageous in conferring protection from COVID-19 (Mishra S. et al., 2020). Correlation analyses carried out in rural and semi rural areas indicate very weak positive correlation of COVID Fatality Rate (CFR) and hypertension; mild negative correlation of CFR with diabetes, implying that CFR is not necessarily related to co-morbidities such as hypertension and diabetes in rural areas.

https://Www.Thehindu.Com/Data/Data-Lower-Covid-19-Fatality-Rate-in-Rural-Areas-Not-Necessarily-Due-to-Lower-Share-of-Co-Morbidities-among-Rural-Population/Article32620632.Ece
reduced to some extent by the Swachh Bharat Mission, a large proportion of rural households avail open defecation and public toilet facilities. Also, many rural households travel long distances to carry drinking water from community source. Social distancing becomes a difficult proposition in such situations (Mishra S. V. et al., 2020). Further, many rural households do not have exclusive rooms for individuals, thus making self isolation difficult. So, careful monitoring of urban-rural movement and augmentation of rural healthcare facilities, wherever necessary, is required to control rise in rural COVID-19 cases and death rates.

**Association of COVID-19 With Other Co-morbidities in India**

Globally, common co-morbidities such as hypertension, diabetes, asthma, cardiovascular disease (CVD), chronic obstructive pulmonary disease (COPD), obesity, chronic kidney disease (CKD), cerebro-vascular accident (CVA), malignancy, and inflammatory conditions have been noted to worsen health status in COVID-19 positive patients (Renu et al., 2020). Medications used in these conditions often lead to upregulation of Angiotensin-converting enzyme 2 (ACE2) receptor; thereby enhancing the possibility of ACE2 mediated viral entry and susceptibility to SARS-CoV-2 infection (Shahid et al., 2020). Communicable diseases such as tuberculosis and HIV-AIDS (Human immunodeficiency virus – Acquired Immuno Deficiency Syndrome) have also been associated with escalated severity and death rate in COVID-19 patients across the world. Sporadic studies from different Indian states/cities such as West Bengal and Jaipur revealed association of one or more co-morbid conditions with deaths in COVID-19 patients. Computational analysis based on Boolean search highlighted diabetes as the most prevalent co-morbidity in Indian COVID-19 patients, followed by hypertension (Singh and Misra, 2020). Co-morbidities in COVID-19 patients result in increased medical complications, incidence of hospitalization and high mortality rate. In order to deal with medical complications arising from COVID-19, it is vital to have knowledge regarding the SARS-CoV-2 strains and the viral mode of action within the host system.

**SARS-CoV-2 Strains Available in India and Their Evolution**

Phylogenetic studies denote the causative agent of COVID-19 as belonging to the family Coronaviridae. Viruses belonging to this family have a single-stranded, (+) sense RNA genome of...
### TABLE 1 | Percentage death rate in urban and rural population across some states of India.

| Sl.No | States         | Urban or rural | Districts considered for study                              | Death rate (in %) (as on 10.06.2020) | Death rate (in %) (as on 04.11.2020) | Death rate (in %) (as on 30.12.2020) |
|-------|----------------|----------------|-------------------------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
| 1     | West Bengal    | Urban          | Kolkata, North 24 Parganas, South 24 Parganas, Howrah, Hooghly | 4.45                                 | 2.24                                 | 2.15                                 |
|       |                | Rural          | Malda, Paschim Medinipur, Purba Medinipur, Nadia, Purulia   | 0.91                                 | 1.08                                 | 1.15                                 |
| 2     | Odisha         | Urban          | Khordha, Nayagarh, Cuttack, Puri, Malkangiri                | 0.44                                 | 0.55                                 | 0.64                                 |
|       |                | Rural          | Ganjam, Balangir, Debagarh, Mayurbhanj, Jagatsinghapur      | 0.12                                 | 0.51                                 | 0.62                                 |
| 3     | Bihar          | Urban          | Patna, Gaya, Nalanda, Bhagalpur, Bengusarai                 | 0.56                                 | 0.68                                 | 0.70                                 |
|       |                | Rural          | Samastipur, Banka, Madhubani, Kaimur, Madhepura             | 0.31                                 | 0.47                                 | 0.50                                 |
| 4     | Uttar Pradesh  | Urban          | Lucknow, Ghaziabad, Agra, Meerut, Kanpur Nagar              | 4.14                                 | 1.75                                 | 1.60                                 |
|       |                | Rural          | Allahabad, Azamgarh, Jaunpur, Sitapur, Gorakhpur            | 2.22                                 | 1.50                                 | 1.53                                 |
| 5     | Jharkhand      | Urban          | Ranchi, Dhanbad, Bokaro, Purbi Singhbhum, Ramgarh           | 1.95                                 | 1.08                                 | 1.12                                 |
|       |                | Rural          | Gridih, Palamu, Hazaribagh, Pashchimi Singhbhum, Simdega    | 0.38                                 | 0.52                                 | 0.57                                 |
| 6     | Madhya Pradesh | Urban          | Bhopal, Indore, Gwaliar, Jabalpur, Ujain                    | 4.21                                 | 1.91                                 | 1.61                                 |
|       |                | Rural          | Dindori, Jhabua, Bhind, Morena, Rewa                       | 2.74                                 | 0.75                                 | 0.73                                 |
| 7     | Haryana        | Urban          | Gurgaon, Panipat, Faridabad, Rohtak, Sonipat                | 2.12                                 | 0.87                                 | 0.92                                 |
|       |                | Rural          | Palwal, Rewari, Mewat, Hajar, Fatehabad                    | 0                                    | 1.19                                 | 1.41                                 |

Death rate = (Death/total confirmed case) × 100; Death rate computed with data obtained on 10.06.2020, 04.11.2020 and 30.12.2020

https://Bing.Com/Covid/Local/India.

~30 kb (Yadav et al., 2020). During the 18th to 19th centuries, viruses from these families were known to cause infections only in animals (Cui et al., 2019). The first time it was discovered in humans was in mid 1965. This strain was referred as HCoV 229E in the United States. This was followed by an outbreak of coronavirus in France caused by another member of the same family, HCoV OC43 that led to 501 confirmed cases in 2000–2001. Till date seven different coronaviruses have been identified in this family that cause infection in humans. There have been five subsequent outbreaks in two decades prior to the recent pandemic caused by SARS-CoV-2 in December 2019 that originated from Wuhan city, China. Bioinformatics based analyses on SARS-CoV-2 genomes isolated from different countries shows its close relation with two bat origin SARS-CoV (bat-SL-CoVZC45 and bat-SL-CoVZXC21). Further, in-depth analysis of SARS-CoV-2 sequence exhibits 96.3% genome similarity with Bat CoV RaTG13 (Yadav et al., 2020). Upon comparison of SARS-CoV-2 with SARS-CoV, six different mutations were identified in ORF1a/b, S, ORF7b, and ORF8 genes. Moreover, similarity between RdRp and 3CLPro proteins has been reported. ORF8 and ORF10 show no homology with that of SARS-CoV strain (Kaur et al., 2020). Till now, no confirmed animal reservoir has been identified, although pangolins are claimed to be natural reservoirs due to the high similarity of the spike region between human SARS-CoV-2 and pangolin SARS-CoV (Andersen et al., 2020). Viruses belonging to this family have an anomalous feature of rapid mutation in their genome that causes variability in the strain. Studies are being conducted to understand the genetic diversity and evolution to establish a reference sequence for SARS-CoV-2 through mathematical modeling and Single Nucleotide Polymorphism (SNP) analysis of all the available sequences (Wang et al., 2020b). In the context of therapeutic drug and vaccine development, it is essential to monitor and track local and global genetic variations in the genome (Yin, 2020). A study of 3636 SARS-CoV-2 RNA sequences from 55 different countries revealed a remarkable mutation in the S protein at D614 amino acid position (D614G) among all the high-frequency mutations and was classified as A2a subtype. These high-frequency mutations in the SARS COV-2 genome have resulted in 11 different clusters of related sequences. Among these, O type is an ancestral type that arose from China. SARS-CoV-2 genotypes A, B, C have been described previously. These have been further divided into subtypes B, B1, B2, and B4 on the basis of mutations in the ORF8 region of SARS CoV-2. Genotype A possesses a mutation that is carried by all the B2 subtypes. A1a, a subtype of A, possesses a mutation similar to type C that may merge all these previously reported genetic variations in one cluster. There is inadequate information about the A2a subtype of SARS-CoV-2 that had spread widely in March. The A2a genotype of SARS CoV-2 consists of a non-synonymous mutation located near the S1-S2 junction similar to the A2 subtype. This non-synonymous mutation could possibly impact viral entry into the host cell (Biswas and Majumder, 2020). Thus, A2a variants could be important genetic variants for the development of effective...
vaccines and drugs against this virus. Further, sub-genotypes A3, A7, A1a, A2, and A6 have evolved from genotype A due to variation at the ORF1a, ORF3a, S, and nucleotide T514C respectively (Samaddar et al., 2020). Another group in India has examined 591 different novel coronaviruses and grouped them in five different clades. A total of 43% synonymous and 57% non-synonymous nucleotide substitutions were observed. The maximum number of non-synonymous substitutions was observed in the S protein (Saha et al., 2020). The presence of four SNPs at genomic positions 241, 3037, 144410, 23405 among 50–60% of the novel coronavirus population was deciphered by combining different bioinformatics (Tiwari and Mishra, 2020). However, epidemiological studies undertaken from time to time and surveillance of genetic variants among humans as well as in animals could be a major aid in the management of such outbreaks.

**VIRAL MODE OF ACTION:**
**IMMUNO-MODULATORY ACTION OF VIRAL PROTEINS**

Binding of SARS-CoV-2 spike (S) protein with host cell angiotensin-converting enzyme 2 (ACE2) aided by TMPRSS2 mediates viral entry. SARS-CoV-2 viral proteins (enlisted in Table 2 and Supplementary Table 5) modulate host immune system and antagonize IFN response. COVID-19 pathophysiology is associated with aggressive pro-inflammatory responses (including IL-6, IL-1β, IP-10, macrophage inflammatory protein 1α (MIP1α), MIP1β and MCP1) and airway damage. Disease severity depends on viral load and the host immune response. Severe COVID-19 patients exhibit high level of pro-inflammatory macrophages, neutrophils and monocytes, which contribute to the cytokine storm with very high plasma levels of TNF, IL-12, IL-6, IL-10, IL-7, G-CSF, IP-10, MIP1α, and MCP1 (Chen et al., 2020; Liao et al., 2020; Zhou et al., 2020). Vigorous pro-inflammatory response leads to airway epithelial and endothelial cell apoptosis, respiratory microvascular damage, vascular leakage and edema, thereby causing hypoxia and compromising blood gas exchange, resulting in acute respiratory distress syndrome (ARDS) (Ye et al., 2020; Zhang B. et al., 2020). Activation of complement pathways has been associated with microvascular injury and thrombosis in severe COVID infection (Magro et al., 2020).

**DIAGNOSTIC METHODS, THERAPEUTIC STRATEGIES AND GOVERNMENT INITIATIVES TO COMBAT COVID-19 IN INDIA**

**COVID-19 Diagnosis in India**

Similarity in signs and symptoms with other respiratory infectious diseases (fever, chills, cough, and shortness of breath) put an extra burden on specialized COVID-19 diagnosis (Kaushik et al., 2020). Clinical manifestation of COVID 19 patients vary day to day and asymptomatic carriers of SARS-CoV-2 pose a challenge to our diagnostic approaches. ICMR and WHO have categorized COVID-19 as mild, moderate, and severe⁹ (Sivasankarapillai et al., 2020). Accurate and rapid diagnosis is needed to minimize substantial morbidity and mortality. Virus isolation, electron microscopy, genomic sequencing, the standard procedures for coronavirus diagnosis are time-consuming and costly. Thus, to examine a large number of patients, serological and laboratory-based methods such as CBC, AST, ALT, creatinine, LDH, ferritin examination, and molecular-based assays are being used on priority (Balachandar et al., 2020). India has set up several diagnostic and labs all over the country to test COVID-19 patients on the basis of qRT-PCR (Kaushik et al., 2020; Lamba, 2020). Diagnosis depends on several SARS-CoV-2 proteins, namely, spike (S), M, envelope (E), N, RdRp and ORF-1b-nsp14 (Alagarasu et al., 2020; Mourya et al., 2020). Initially, in India the first two SARS-COV-2 viruses were identified and confirmed by screening for viral genes (E, RdRp, and N protein of SARS-CoV-2) in 881 suspected cases by RT-PCR and next-generation sequencing (Yadav et al., 2020). The limited supply of positive controls has been overcome by the introduction of in vitro transcribed RNA from the National Institute of Virology (NIV) (Choudhary et al., 2020). SOPs for types of specimen collection and transportation were initially documented by ICMR-NIV (Gupta et al., 2020). To enhance the speed of detection, various rapid detection kits, CT scan and X-ray based techniques have been introduced from time to time. However, lack of accuracy of these techniques has prevented them from being used as standard procedures (Iyer et al., 2020). The production of IgG and IgM against COVID-19 takes 10–15 days from infection. This is a limitation for any antigen and antibody-based rapid detection kit (Hou et al., 2020). Recently, a CRISPR based fast and highly accurate diagnostic approach for COVID-19 has been introduced which employs nucleic acid readout of SARS-COV-2 (Lotfí and Rezaei, 2020). However, its implementation is highly challenging. CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), India has also developed an efficient and accurate detection tool named Feluda based on CRISPR-Cas9 technology, as an alternative to current gold standard RT-PCR technique. Feluda has received approval from the DCGI for commercial launch¹¹. In continuing efforts to discover a fast and rapid detection technique for SARS-CoV-2, an aptamer based assay has been developed at Translational Health Science and Technology Institute (THSTI). In this assay, nasal swab is used as the specimen for detection¹². Gargle lavage sample collected from COVID-19 patients was identified as an easy, alternative showing comparable efficiency as nasopharyngeal and oropharyngeal swab samples (Mittal et al., 2020). Monitoring

---

¹⁰https://www.expresshealthcare.in/covid19-updates/icmr-revises-treatment-protocol-for-covid-19-patients/421792/

¹¹https://Science.Thewire.In/the-Sciences/Explained-Feluda-Covid-19-Test-India-Crispr-Technology/

¹²https://Journosdiary.Com/2020/07/12/Aptamer-Based-Assay-Developed-for-Coronavirus-Detection/
TABLE 2 | Comparative list of SARS-CoV and SARS-CoV-2 viral proteins involved in modulating the host anti-viral immune response.

| Sl.No. | Viral protein | Category | Host immuno modulating function of viral proteins |
|--------|---------------|----------|---------------------------------------------------|
| 1.     | M protein     | Structural Protein (Important component of viral envelope) | Increased M protein expression is linked with RIG-I, TBK1, IKKe, and TRAF3 and hence, prevention of IRF3 and IRF7 activation. This results in significant decrease in induction of the interferon-β promoter by dsRNA (Weiss and Leibowitz, 2011). |
| 2.     | N protein     | Structural Protein (Encodes for Nucleocapsid protein) | Overexpression is associated with decreased IFN response via inhibition of IRF3 and NF-κB responsive promoter mediated activation (Weiss and Leibowitz, 2011). |
| 3.     | Nsp1          | Non-Structural Protein | Suppresses the activation of IRF3, c-Jun and NF-κB, thereby blocking the interferon response and subsequent activation of interferon-dependent anti-viral proteins (such as ISG15 and ISG56) (Weiss and Leibowitz, 2011). Modulates and suppresses the host anti-viral immune response (Gordon et al., 2020). |
| 4.     | Nsp3          | Non-Structural Protein | Serves as papain like protease with de-ubiquitinating activity; could act as Type I Interferon antagonist (Weiss and Leibowitz, 2011). |
| 5.     | Nsp13         | Non-Structural Protein | – |
| 6.     | Nsp15         | Non-Structural Protein | – |
| 7.     | ORF3a         | Accessory Protein | Raises level of fibrinogen in lungs. Activates the NLRP3 inflammasome (Chen et al., 2019). Activates NF-κB and JNK which in turn leads to upregulated expression of pro-inflammatory cytokines (such as IL8 and RANTES) (Narayanan et al., 2008). Mediates IL-1β and IL-18 secretion (Chen et al., 2019; Gordon et al., 2020). Induces increased apoptosis via caspase 8 and caspase 9-mediated pathways. Bax, p53 and p38 MAP kinase are also involved in ORF3a mediated apoptosis (McBride and Fielding, 2012; Chen et al., 2019). |
| 8.     | ORF3b         | Accessory Protein | Enhances the production of cytokines and chemokines by regulating the transcriptional activity of RUNX1b. Inhibits Type I interferon (IFN) production and signaling (Narayanan et al., 2008; McBride and Fielding, 2012). |
| 9.     | ORF6          | Accessory Protein | Promotes DNA synthesis, Hampers Type I IFN production and signaling (Narayanan et al., 2008; McBride and Fielding, 2012). |
| 10.    | ORF7a         | Accessory Protein | Triggers inflammatory response through activation of NF-κB and IL8 promoter region (Narayanan et al., 2008). Promotes pro-inflammatory cytokines (such as IL8 and RANTES) production (McBride and Fielding, 2012). |
| 11.    | ORF8b         | Accessory Protein | Blocks the IFN-β signaling pathway by ubiquitin-proteasome mediated degradation of IRF3 (Wong et al., 2018). |
| 12.    | Orf9b         | Accessory Protein | – |
| 13.    | Orf9c         | Accessory Protein | – |

Detection Equipment

Standard diagnosis for infection requires real-time thermal cyclers which are used to perform RT-PCR, a robust and reliable detection technology (Corman et al., 2020). Technology centres under MSMEs began manufacturing components of Real Time
Quantitative Micro PCR System in order to assemble the devices at a manufacturing unit in Visakhapatnam to ramp up the testing procedure\textsuperscript{13}. Apart from RT-PCR based testing, other approaches have also been demonstrated which involve two-step detection methods involving more affordable thermal cyclers (conventional PCR) and fluorescence spectrometers\textsuperscript{14}.

**The Treatment of SARS-CoV-2 Infection and COVID-19: The Present Scenario**

The SARS-CoV-2 infection and the COVID-19 pandemic have posed an unprecedented challenge to the medical fraternity. The treatment is restricted to the best supportive care and experimental medications. Targeting the viral entry, interaction of the virus with its host and the downstream signaling pathways using novel or repurposed drugs, is one of the strategies for the management of COVID-19. Several agents (enlisted in Table 3 and Supplementary Table 6) have been tried based on their role in similar viral infections, or their prospective action on the novel corona virus.

Indian Pharmaceuticals Cadila has tested the immunomodulator drug named Sepsivac (containing heat-killed *Mycobacterium W* (Mw)), on COVID-19 patients at PGIMER, Chandigarh in partnership with the Council of Scientific and Industrial Research (CSIR) to reduce the mortality of critically ill COVID-19 patients and have obtained promising results\textsuperscript{15}.

Apart from these drugs, the US FDA has approved use of convalescent plasma for severe life-threatening COVID infection as an investigational new drug (Duan et al., 2020). Its use has been documented in a series of cases (Huang et al., 2020; Zeng et al., 2020)\textsuperscript{16}. One small trial with five ventilated patients showed success. Its role is still not clear and US FDA is facilitating the use of hyperimmune globulin for COVID treatment (Mehta et al., 2020). US FDA recommended the use of convalescent plasma for emerging infections including COVID-19 on May 1, 2020 (see text footnote 2). The Indian Council of Medical Research (ICMR) began clinical trials with convalescent plasma in India to evaluate its safety and efficiency in controlling COVID-19 symptoms\textsuperscript{17, 18}. ICMR has recommended use of convalescent plasma for COVID-19 therapy. A plasma bank has been established in Delhi and Project PLATINA has been established in Maharashtra for treatment cum trial with plasma therapy\textsuperscript{19}.

Another approach for developing drugs targeting host immunity has been to express SARS-CoV-2 proteins in human cell lines and identify their human protein interacting partners. Of 332 interactions, 66 human proteins were found as druggable candidates that could be targeted by 29 FDA approved drugs, 12 compounds in clinical trials and 28 compounds in preclinical stage (Gordon et al., 2020). Further screening has helped in the identification of two pharmacological candidates that inhibit mRNA translation and are predicted to regulate Sigma1 and Sigma2 receptors. Besides, inhibitors targeting endocytosis have shown activity in vitro against other coronaviruses such as SARS CoV and MERS-CoV. These include chlorpromazine, ouabain and bufalin (de Wilde et al., 2014; Burkard et al., 2015). Their efficacy against SARS CoV-2 is yet to be tested. However, very high EC\textsubscript{50}/C\textsubscript{max} (half-maximal effective concentration value/peak serum concentration level) ratio at the typical dosages used is limiting their possible clinical use.

Natural killer cells play a role in the clearance of SARS-CoV. NK cell based products are in various stages of trial as anti-COVID-19 agents. The US-based Company Celularity has developed placenta derived NK cells CYNK-001 (Tu et al., 2020). Recombinant Interferon Type I exhibits broad spectrum activity against coronaviruses (Cinatl et al., 2003b; Sheahan et al., 2020). Clinical trials are currently in motion for the treatment of COVID-19 pneumonia (NCT04293887). Trials are also ongoing to test the efficacy of mesenchymal stem cells from the umbilical cord and dental pulp to attenuate the inflammatory response of COVID-19 (NCT04293692, NCT04269525, NCT04288102, NCT04302519). The World Health Organization’s (WHO) Solidarity trial including randomized and controlled clinical trials are set to test several protocols against COVID-19.

**COVID-19 Vaccine Developments – Present Indian Scenario**

In the global fight against COVID-19, scientists from different countries are trying to decipher a potential therapeutic drug, vaccine, and early diagnostic tools. The SARS-CoV-2 'S' protein interacts with the ACE2 receptor and is a glycosylated protein, making this protein a good candidate for vaccine development (Othman et al., 2020). Globally several vaccine generation methods are being used against COVID-19, including a live attenuated vaccine, inactivated vaccine, replicating viral vector, non-replicating viral vector, DNA vaccine, peptide-based vaccine, recombinant protein, virus-like particle (VLP) and mRNA-based vaccine (Le et al., 2020). According to the WHO, there are currently 63 COVID-19 vaccines in clinical development and 172 vaccine candidates in pre clinical developmental stage as on 6th January, 2021 (see text footnote 3). Out of these 63 vaccines, about 20 vaccine candidates are in Phase III clinical trial (as enlisted in Table 4). Among these 20 vaccines, the efficacy report is available for five vaccines that include "BNT162 (Pfizer), mRNA 1273 (Moderna), chAdOx1nCOV19 (University of Oxford and AstraZeneca), BBIBP-CorV (Sinopharm) and Sputnik-V (Gamaleya Research Institute)\textsuperscript{20}. However, only

\textsuperscript{13}https://Pib.Gov.In/Pressreleasepage.Aspx?PrId=1623027
\textsuperscript{14}https://Www.Hindustantimes.Com/India-New/Lisc-Comes-up-with-an-Affordable-Two-Step-Method-to-Scale-up-Rt-Pc-Testing/Story-Xbhtylgifldqphor6p60.html
\textsuperscript{15}https://Www.Hindustantimes.Com/Health/Indian-Trials-on-Multiple-Covid-19-Drugs-Make-Progress-Have-Atmanirbhar-Bharat-Tilt/Story-Nk0owrrrsyragqhvrk2a9i.html
\textsuperscript{16}https://Www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-coordinates-national-effort-develop-blood-related-therapies-covid-19
\textsuperscript{17}https://Www.Indialegallive.Com/Special-Story/Convalescent-Plasma-Therapy-a-Treatment-for-Covid-19/
\textsuperscript{18}https://Www.Medrxiv.Org/Content/10.1101/2020.09.03.20187252v2
\textsuperscript{19}https://Swachhindia.Ndtv.Com/Coronavirus-Outbreak-Explained-What-Is-Convalescent-Plasma-Therapy-and-How-Effective-Is-It-in-Treating-Covid-19-Patients-46568/
\textsuperscript{20}https://Www.Thelancet.Com/Journals/Lancme/Aarticle/Piis2666-5247(20)30226-3/fulltext
### TABLE 3 | List of immuno-modulating drugs which are tried for COVID-19.

| Sl.No. | Name of drugs | Type of anti viral or immune boosting action |
|--------|---------------|---------------------------------------------|
| 1.     | Chloroquine and Hydroxychloroquine (HCQS) | May keep the virus out of host cells by blocking host receptor glycosylation or by breaking down viral protein production. May lead to suppression of pH-dependent steps of viral replication (Choudhary and Sharma, 2020). May exert immune-modulatory effects by inhibiting TNF-α and IL6 production and may serve as a potent autophagy inhibitor. Active against SARS-CoV-2 in vitro (Yao et al., 2020). Leads to fast symptomatic improvement (fever, cough and chest imaging) (Cortegiani et al., 2020). HCQS and azithromycin combination leads to early viral clearance compared to HCQS alone (Gautret et al., 2020). US-FDA have cautioned against the use of HCQS for COVID-19 outside hospital settings https://Medicaldialogues.In/Medicine/News/Fda-Cautions-against-Use-of-Chloroquine-or-Hcqs-in-Covid-19-65165 (accessed on May 5,2020). |
| 2.     | Corticosteroids | Exert immune-modulatory effects by inhibiting expression of genes encoding inflammatory molecules (Shaffer, 2020). Dexamethasone proven to be a life saving drug for severe COVID-19. |
| 3.     | Tocilizumab, Sarilumab and Situximab | Monoclonal antibody (MAb) antagonists of the IL6 receptor. Drugs commonly used for treatment of rheumatoid arthritis. Severe forms of COVID-19 are associated with elevated levels of IL6, causing acute respiratory distress syndrome (ARDS) even upon reduction of viral load. These MAbs may play a vital role in reducing IL6 level and reduce instances of ARDS in COVID-19 patients (Chan et al., 2013; Luo et al., 2020; Michot et al., 2020; Shaffer, 2020). |
| 4.     | Fluvoxamine | This serotonin re-uptake inhibitor may serve as an immune modulatory agent and shut down the inflammatory cascade from the endoplasmic reticulum by binding to the sigma-1 receptor (Shaffer, 2020). |
| 5.     | Remdesivir | Antiviral pro drug. The active analog of the pro drug inhibits the viral RNA dependent RNA polymerase (RdRp) and preventing viral replication. Remdesivir also evades the proofreading mechanism (excisionnuclease) of coronavirus (Ferner and Aronson, 2020; Wang M. et al., 2020) https://Www.Fda.Gov/Media/137564/Download (downloaded on May 5, 2020). |
| 6.     | Azithromycin | Broad spectrum macrolide antibiotic. Used mainly for treatment of pulmonary, enteric and genitourinarytract infections. Acts as an acidotropic lipophilic weak base which modifies the pH of the endosome and trans-Golgi network and affects viral replication. Interferes with viral entry by binding to viral spike (S) protein and humanreceptor protein ACE2 (angiotensin converting enzyme-2). May exert interferon mediated anti viral immune response (Choudhary and Sharma, 2020; Damle et al., 2020). |
| 7.     | Baricitinib, Fedratinib, and Ruxolitinib | Potent JAK inhibitors selectively inhibiting JAK-STAT signaling https://Www.Chictr.Org.Cn/Showprojen.Aspx?Proj=49088 (Spinelli et al., 2020; Stebbing et al., 2020). Exerts anti-inflammatory effects. Might be effective in controlling the cytokine storm in COVID-19. Baricitinib is also predicted to hamper ACE2 mediated endocytosis (Richardson et al., 2020). |
| 8.     | Gimsilumab, Lenzilumab, Namilumab | These are anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies. Blocks the inflammatory pathway in its early steps. |
| 9.     | Thalidomide | Synthetic glutamic acid derivative. Possess anti-inflammatory, anti-fibrotic, anti-angiogenesis, and immuno-modulatory effects. Inhibits and downregulates COX2, PGE2, TNF-α, IL6 and IL1. Used to treat severe H1N1 influenza-associated lung injury. Being tested for its efficacy in treating cytokine storm and reducing lung injury and respiratory complications in COVID-19 https://Clinicaltrials.Gov/Ct2/Show/Nct04273529;https://Clinicaltrials.Gov/Ct2/Show/Nct04273581 (Khali et al., 2020). |
| 10.    | Nafamostat and Camostat | Serine protease inhibitors which prevent SARS-CoV-2 entry by acting as antagonists to the serine protease TMRPSS2 (Yamamoto et al., 2016; Hoffmann et al., 2020; Zhang H. et al., 2020). |
| 11.    | Famotidine | H2 receptor antagonist; may bind to SARS-CoV-2 encoded papain like protease and impair entry of SARS-CoV-2 (Shaffer, 2020). |
| 12.    | Ivermectin | Broad spectrum anti-parasitic macrolide drug. Functions by binding and impairing the cell transport proteins that are vital for entry into the nucleus (Choudhary and Sharma, 2020). |
| 13.    | Favipiravir | Inhibits virus replication by binding and blocking the RdRp enzyme (Furuta et al., 2013). Its incorporation in RNA also terminates viral protein synthesis (Jin et al., 2013). Classically used against influenza virus. Also acts on SARS-CoV-2 replication; used for mild and moderate COVID cases (Agrawal et al., 2020). |

(Continued)
AstraZeneca has entered phase III trials in collaboration with Covishield, the vaccine developed by Oxford University and origin are presently in various stages of clinical trial in India. Additionally, indigenous vaccines, several non indigenous vaccines of foreign origin are also being initiated for this vaccine. Besides these, Dr. Reddy's Laboratories Limited and Sputnik LLC (Russia) have been jointly conducting the clinical trial of Sputnik-V, the world's first registered vaccine in India. This vaccine, ranking among the world's top 10 vaccine candidates is presently in Phase II Human Clinical Trial in India. The Biological E's novel Covid-19 vaccine is also in the Phase I/II Human Clinical Trial in India (see text footnote 5). Ecological studies have highlighted lower number of infections and reduced COVID-19 mortality in countries, where BCG vaccination is made mandatory (Urashima et al., 2020). Randomized controlled trials of BCG-Danish have been conducted in Netherlands and Australia (NCT04327206, NCT04328441). Serum Institute, Pune, India has conducted phase III trial of BCG vaccine VPM1002 to evaluate cross-protection to COVID-19. BCG vaccine could serve as a booster of innate immunity against COVID-19 via metabolic and epigenetic changes in a process called trained immunity (Netea et al., 2020).

In India, COVAXIN, an indigenous inactivated COVID-19 vaccine, stable at 2–8°C, manufactured by Bharat Biotech (Hyderabad, India) has currently entered the Phase III Human clinical trial and has recently been given emergency approval in India by the DCGI (see text footnote 7). A plasmid DNA based vaccine, ZyCoV-D has been developed by Ahmedabad-based pharma company Cadila Healthcare (Zydus Cadila). It has been claimed that this vaccine is stable for 3 months at a temperature of 30°C and longer at 2–8°C. This thermostability could be beneficial for nationwide vaccination program due to minimalistic cold storage requirements. Phase III human clinical trials are being initiated for this vaccine. Besides these indigenous vaccines, several non indigenous vaccines of foreign origin are presently in various stages of clinical trial in India. Covishield, the vaccine developed by Oxford University and AstraZeneca has entered phase III trials in collaboration with the Serum Institute, Pune, India. Serum Institute has applied to DCGI for emergency regulatory authorization for Covishield use in India and has submitted additional requisite vaccine datasheet in this regard. This vaccine has been approved for emergency use in United Kingdom and has become the first COVID-19 vaccine candidate to have obtained emergency approval in India (see text footnote 4). Covishield has the advantage of storage at 2–8°C. Besides this, Dr. Reddy's Laboratories Limited and Sputnik LLC (Russia) have been jointly conducting the clinical trial of Sputnik-V, the world's first registered vaccine in India. This vaccine, ranking among the world's top 10 vaccine candidates is presently in Phase II Human Clinical Trial in India. The Biological E's novel Covid-19 vaccine is also in the Phase I/II Human Clinical Trial in India (see text footnote 5). Ecological studies have highlighted lower number of infections and reduced COVID-19 mortality in countries, where BCG vaccination is made mandatory (Urashima et al., 2020). Randomized controlled trials of BCG-Danish have been conducted in Netherlands and Australia (NCT04327206, NCT04328441). Serum Institute, Pune, India has conducted phase III trial of BCG vaccine VPM1002 to evaluate cross-protection to COVID-19. BCG vaccine could serve as a booster of innate immunity against COVID-19 via metabolic and epigenetic changes in a process called trained immunity (Netea et al., 2020).

Another important vaccine, BNT162 from Pfizer, which has already been rolled out in United Kingdom, United States and received emergency use approval in more than 10 countries, has extreme cold chain and storage requirement at −75°C to keep its potency intact. Similarly, Moderna vaccine also has stringent storage requirement at −20°C. Such stringent refrigeration needs may be difficult to achieve in developing countries and may render mass vaccination in India extremely challenging. Although India has cold storage facilities, they

### TABLE 3 | Continued

| Sl.No. | Name of drugs | Type of anti viral or immune boosting action |
|-------|---------------|---------------------------------------------|
| 14.   | Lopinavir/Ritonavir | Antiretroviral protease inhibitors, successfully used in HIV infection (Huang et al., 2015). Combination of lopinavir/ritonavir used successfully for treatment of SARS with significantly fewer adverse clinical outcomes (Chu et al., 2004). Lopinavir/Ritonavir with Interferon 1b found promising in the marmoset model (Chan et al., 2015). |
| 15.   | APN01 | Soluble form of ACE2 delivered in high concentrations. Could potentially block SARS-CoV-2 entry into target cells. Under clinical trial. |

three vaccines are available with the data published in peer reviewed journals till 5th January, 2021 namely, mRNA1273, BNT162, and chAdOx1nCoV19 (Baden et al., 2020; Polack et al., 2020; Voysey et al., 2020). Supporting data to answer such important question such as duration of herd immunity upon vaccination, requirement of booster doses for long term immunity and whether vaccine could help in the prevention of transmission is available for only chAdOx1nCoV19 vaccine till to date. Further, safety of the above mentioned vaccines needs to be evaluated in the populations that have not been included in the trials such as pregnant women (see text footnote 21).

Apart from this, global mass immunization also encountered several challenges including financial, logistic and vaccine storage-related issues. The upper middle income countries started the vaccination in 2020. However, successful global vaccination or complete eradication of virus is possible only when low income and middle income countries get immunized in parallel. To overcome this situation, an International initiative termed COVAX facility has been set up to ensure equitable access to vaccine doses in Low income and middle income countries (LCMICs). COVAX aims at fixed vaccination for 20% of population belonging to the LCMICs by 2021. The vaccine will be provided by the AstraZeneca21.

In India, COVAXIN, an indigenous inactivated COVID-19 vaccine, stable at 2–8°C, manufactured by Bharat Biotech (Hyderabad, India) has currently entered the Phase III Human clinical trial and has recently been given emergency approval in India by the DCGI (see text footnote 7)22. A plasmid DNA based vaccine, ZyCoV-D has been developed by Ahmedabad-based pharma company Cadila Healthcare (Zydus Cadila). It has been claimed that this vaccine is stable for 3 months at a temperature of 30°C and longer at 2–8°C. This thermostability could be beneficial for nationwide vaccination program due to minimalistic cold storage requirements. Phase III human clinical trials are being initiated for this vaccine. Besides these indigenous vaccines, several non indigenous vaccines of foreign origin are presently in various stages of clinical trial in India. Covishield, the vaccine developed by Oxford University and AstraZeneca has entered phase III trials in collaboration with

---

21https://www.thelancet.com/pdfs/journals/lancet/PIIS2666-5247%2820%2930226-3.pdf
22https://www.indiatoday.in/health/story/why-covaxin-covishield-best-option-for-india-against-covid19-pandemic-1755517-2021-01-03
23https://www.pfizer.com/news/hot-topics/covid_19_vaccine_u_s_distribution_fact_sheet
24https://www.indianexpress.com/article/explained/covid-19-vaccine-storage-optimal-temperature-cold-chain-india-explained-quixplained-7063369/
| Sl.No. | Name of vaccine | Nature of vaccine | Clinical Trial Phase | Country of origin |
|-------|----------------|-------------------|----------------------|-------------------|
| 1     | Ad5-nCoV       | Recombinant vaccine (adenovirus type 5 vector) | Phase III | CanSino Biologics Inc/ Beijing Institute of Biotechnology (China) |
| 2     | Covishield (Code name: AZD1222) | Replication-deficient viral vector vaccine (adenovirus from chimpanzees) | Phase III (received approval for emergency use in United Kingdom and India) | The University of Oxford; AstraZeneca; IQVIA; Serum Institute of India (Multinational) (see text footnote 4) | https://www.bbc.com/news/health-55280671 |
| 3     | CoronaVac      | Inactivated viral vaccine (formalin with alum adjuvant) | Phase III | Sinovac (China) |
| 4     | COVAXIN        | Inactivated viral vaccine | Phase III (approved for emergency use in India) | Bharat Biotech; National Institute of Virology (India) (see text footnote 7) |
| 5     | JNJ-7843735 (formerly Ad26.COV2-S) | Non-replicating viral vector | Phase III | Johnson & Johnson (Janssen Pharmaceutical) (United States) |
| 6     | mRNA-1273      | mRNA-based vaccine | Phase III (received approval and presently in use in United States) | Moderna; National Institute of Allergy and Infectious Diseases (NIAID) (United States) | https://www.nature.com/articles/d41586-020-03593-7 |
| 7     | New Crown COVID-19 Vaccine | Inactivated vaccine | Phase III | Wuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm, China) | https://www.precisionvaccinations.com/vaccines/new-crown-covid-19-vaccine |
| 8     | NVX-CoV2373    | Protein based vaccine (Full length recombinant SARS CoV-2 spike protein nanoparticle vaccine adjuvanted with Matrix M) | Phase III | Novavax (Maryland); Serum Institute of India | https://www.novavax.com/news-releases/news-release-details/Novavax-Announces-Covid-19-Vaccine-Clinical-Development-Progress |
| 9     | BNT162 (3 LNP-mRNAs) | mRNA-based vaccine | Phase II/III (Already in use in United Kingdom and United States) | Pfizer; BioNTech; Fosun Pharma; Jiangsu Provincial Center for Disease Prevention and Control (Multinational) | https://www.nature.com/articles/d41586-020-03593-7 |
| 10    | Sputnik-V Vaccine (rAd26- S+Ad5-S) | Adeno viral vector based technology | Phase III | Gamaleya Research Institute; Health Ministry of the Russian Federation (Russia) |
| 11    | BBIBP-CorV     | Inactivated viral vaccine | Phase III | Sinopharm + Beijing Institute of Biological Products (China) (Xia et al., 2021) |
| 12    | Recombinant SARS-CoV-2 vaccine | DNA based vaccine | Phase III | Anhui Zhifei Longcom Biopharmaceutical; Institute of Microbiology, Chinese Academy of Sciences (China) |
| 13    | INO-4800       | DNA based vaccine | Phase II/III | Inovio Pharmaceuticals and International Vaccine Institute (South Korea) |
| 14    | CoVLP          | Coronavirus-Like Particle based vaccine | Phase II/III | Medicago Inc. (Canada) |
| 15    | CvCoV          | DNA based vaccine | Phase II/III | CureVac AG (Germany) |
| 16    | UB-612         | Multitope peptide based S1-RBD-protein based vaccine | Phase II/III | COVAXX; United Biomedical Inc |
| 17    | ZyCoV-D nCoV vaccine | DNA based vaccine | Phase III | Cadila Healthcare Ltd. Zydus Cadila, (India) | https://econometrics.indiamart.com/markets/stocks-news/cadila-healthcare-gains-3-as-dcg-plays-phase-ii-trials-of-covid-vaccine/articleshow/80091363.cms |
| 18    | QazCovid-in    | Inactivated viral vaccine | Phase III | Research Institute for Biological Safety Problems (Rep of Kazakhstan) |
| 19    | SARS-CoV-2 vaccine (vero cell) | Inactivated viral vaccine | Phase III | Institute of Medical Biology; Chinese Academy of Medical Sciences (China) |
| 20    | AG0301-COVID19 | DNA based vaccine | Phase II/III | AnGes + Takara Bio + Osaka University (Japan) |

**Vaccine Information obtained from World Health Organization (WHO) as on 06.01.2021 (see text footnote 3).**
Neutralizing Antibodies: Another Approach

Neutralization of the virus by antibodies is an important strategy for containing SARS-CoV-2. In SARS-CoV, the RBD122 (amino acids 318 to 510) of the S protein is primarily being targeted by neutralizing antibodies (Wong et al., 2004). The RBD of SARS-CoV and SARS-CoV-2 are poorly conserved, so the majority of the monoclonal antibodies to SARS-CoV do not bind with or neutralize SARS-CoV-2 (Wang et al., 2020a). Therapeutic monoclonal antibodies to SARS-CoV-2 are being developed with the aid of phage library display, cloning of human B cell sequences from recovering patients and mouse immunization and hybridoma isolation. Anaive semi synthetic library has been used to identify the anti-SARS-CoV-2 RBD human monoclonal antibody. This approach holds promise since the entire RBD remains conserved as of now (Parray et al., 2020). However, caution must be exercised, since animal studies of SARS-CoV infection show that neutralizing antibodies to S protein may increase lung injury by aggravating inflammatory responses (Liu et al., 2019). Anti-S-IgG mediated proinflammatory responses occur due to binding of virus-anti-S-IgG complex with the Fc receptors (FcR) present on monocytes and macrophages (Liu et al., 2019). In addition, virus-anti-S-IgG complex may trigger the classical complement pathway leading to cellular damage.

Indian Government Initiatives and Strategies to Combat COVID-19

Personal Protective Equipment

Personal Protective Equipment (PPE) including face piece respirators, gloves, shoe covers and face shields are necessary for the protection of health workers from infection (26). N95 respirators, surgical masks or cloth masks are recommended to prevent respiratory transmission. Cloth masks may possibly be cost-effective in preventing community transmission in densely populated Asian countries (Sra et al., 2020). Unlike N95 respirators, simple cloth and surgical masks are non-disposable and can be potentially decontaminated routinely using alcohol/detergent washing, and moist heat treatment (Viscusi et al., 2009). To prevent contact transmission, disposable gloves are recommended for patient examination. Government of India is funding enterprises and enabling transfer of advanced technology for increased PPE production (27). However, supply of raw materials may be dependent on import and could be a bottleneck for large scale production in India (Feinmann, 2020).

Disinfection Instruments

COVID-19 may potentially remain transmissible on inanimate surfaces up to several days. Effective disinfection could be achieved using biocidal chemicals such as 70% ethanol, 0.1% aqueous sodium hypochlorite and 0.5% hydrogen peroxide solutions (Kampf, 2020; Kampf et al., 2020). 60–70% ethanol is recommended for sterilizing high-end biomedical equipment, while 0.1% aqueous sodium hypochlorite could be a viable solution for decontamination of large areas such as mass transit systems, hospital outdoors etc. Scientists from the
Council of Scientific and Industrial Research (CSIR), India have claimed to develop a spraying procedure by using induction charged electrostatic spraying apparatus involving lower amounts of chemicals, charge based disinfection and large coverage in comparison with conventional high-volume sprayers\(^{38,39}\) (Lyons et al., 2011). In line with other countries, drone-based disinfection methods have been proposed by Indian enterprises\(^ {40}\). Concern about the potential hazards of inhaling the aerosolized disinfectants still poses a challenge for large area disinfection (Kim et al., 2020).

**Biomedical Equipment**

Various medical equipment such as ventilators, sensor equipments including pulse-oximeter, infrared thermometer, multi parametric photo plethysmography (PPG) sensor, portable X-ray machine, fiberoptic bronchoscopes, video laryngoscopes, are required in monitoring and treatment of COVID-19 patients (Wax and Christian, 2020). The ventilator is a crucial equipment for critically ill patients with respiratory problems (Iyengar et al., 2020). Ventilators are costly (~$30,000) and there is a world-wide shortage of ventilators during the pandemic. India alone has a requirement for tens of thousands of ventilators\(^ {41}\). There is global endeavor to enhance production, lower cost and find alternatives. Engineers from Rail Coach Factory have claimed production of a low-cost prototype ventilator\(^ {42}\). Scientists at the CSIR laboratories are also developing 3D printed automatic ventilators and mechanical ventilators\(^ {43}\) (Iyengar et al., 2020). An alternative for the ventilator, “Artificial Manual Breathing Unit (AMBU)” has been designed by researchers from the Postgraduate Institute of Medical Education and Research, Chandigarh (Iyengar et al., 2020). Recently, an Indian manufacturer has reported production of state-of-the-art ventilator costing less than $2000 (Agrawal, 2020).

**Indigenous Medicinal Plants for Combating COVID-19**

Antiviral herbal therapy has made enormous progress in the past decade (Dhama et al., 2018). Various medicinal plants and bioactive phyto-metabolites have been widely explored for effective control of several viral diseases such as influenza, hepatitis, human immunodeficiency virus (HIV), herpes simplex virus (HSV) and coxsackievirus infections (Akram et al., 2018). India harbors a diverse variety of medicinal plants and herbs with therapeutic potential (Mohanraj et al., 2018). The major indigenous medicinal plants with immuno-modulatory properties, which can potentially be explored for their role in boosting immunity and rendering protection from SARS-CoV-2 infection, have been summarized in Table 5 and Supplementary Table 7.

The Ministry of Ayush under the Govt. of India has recommended use of indigenous herbal plants and spices namely, tulsi, cinnamon, dry ginger, black pepper, turmeric, coriander, cumin and garlic for enhancing immunity\(^ {44}\). Besides, the Ministry of Ayush has formulated a collection of four ayurvedic herbs namely, ashwagandha, guduchi, yashthimadhu, peepli; and a drug named Ayush 64 for combating COVID-19. The Ministry of Ayush along with the CSIR have initiated the process of validating the efficacy of these formulations against COVID-19 in the month of May, 2020 and the outcomes of these trials are expected to be available soon\(^ {45,46,47}\).

**Artificial Intelligence in Combating COVID-19**

The worldwide outbreak of SARS-CoV-2 has resulted in a tremendous dearth of clinical equipment. In order to contain the pandemic effectively, large scale testing and diagnosis are required. This is evident from the successful containment of SARS-CoV-2 virus in countries that have been able to perform mass testing of possibly infected people and contact tracing. RT-PCR serves as the gold standard test for validating SARS-CoV-2 infection. Inadequate testing capability in most countries, along with the high dependency of the RT-PCR test on the swab technique, has spurred the need to search for alternative methods that allow COVID-19 diagnosis.

**CT scan in COVID-19**

The chest X-ray and thoracic computed tomography (CT) are examples of easily accessible medical imaging equipment, which assists clinicians in diagnosis. CT images may serve as a visual indicator of coronavirus infection for radiologists (Duncan and Ayache, 2000). While RT-PCR may take up to 24 h and needs multiple tests for conclusive results, chest CT combined with certain health symptoms can be used as an effective diagnostic tool in clinical practice for rapid screening of COVID-19 patients. There is a high chance that COVID-19 patients can be diagnosed accurately by using chest radiography images (van Ginneken et al., 2001; Sluimer et al., 2006). However, manual examination of CT scans for COVID-19 diagnosis is a labor-intensive and time-taking process. Besides, clinical presentation of COVID-19 in CT images is similar to other forms of viral pneumonia, which makes diagnosis even more difficult. A dependable computer-aided diagnostic system for COVID-19

---

\(^{38}\)https://Www.Igi-Global.Com/Chapter/Fundamentals-of-Electrostatic-Spraying/232957
\(^{39}\)https://Www.Tribuneindia.Com/News/Nation/Csir-Develops-Electrostatic-Disinfection-Technology-to-Combat-Covid-78098
\(^{40}\)https://Pib.Gov.In/Pressreleasepage.Aspx?Prid=1620351
\(^{41}\)https://Www.Medrxiv.Org/Content/10.1101/2020.03.26.20044511v1.FullPdf
\(^{42}\)https://Www.Tribuneindia.Com/News/Nation/Rail-Coach-Factory-Kapurthala-Develops-Ventilator-66118
\(^{43}\)https://Www.Csir.Res.In/Csir-Labs-Initiatives-against-Covid-19

---

\(^{44}\)https://www.ayush.gov.in/
\(^{45}\)https://Newsonair.Nic.In/News?Title=Ministry-of-Ayush%2c-Csir-Working-Together-on-Validating-Four-Ayush-Formulations-against-Covid-19&Id=388575 (accessed on June 22, 2020).
\(^{46}\)https://timesofindia.indiatimes.com/life-style/health-fitness/home-remedies/covid-19-ministry-of-ayush-starts-clinical-trials-for-ashwagandha-and-4-other-ayurvedic-herbs-here-is-what-you-need-to-know/photos/story/75692669.cms
\(^{47}\)https://www.hindustantimes.com/india-news/trials-for-4-ayush-formulations-against-covid-19-begins-under-ayush-ayush-64-and-4-ayurvedic-herbs/story-S6h8Tj0r7ZMsP7TrfY1tbI.html
**TABLE 5 | List of medicinal plants with major immune modulating properties.**

| Sl.No. | NAME OF PLANTS | Type of anti viral or immune targeting effects exerted |
|-------|----------------|-----------------------------------------------------|
| 1.    | Turmeric       | Curcumin in turmeric is an immune-modulatory agent.  |
|       |                | Has an anti-viral, anti-microbial, anti-inflammatory and anti-oxidant activity. |
|       |                | Reduces pro-inflammatory cytokines like TNF-α, IFN-γ, IL-1 and IL-8 via interaction with signal transducers such as NF-κB, JAKs/STATs, MAPKs and β-catenin (Leili et al., 2017; Kakhhaie et al., 2019). |
| 2.    | Ashwagandha    | Activates immune response. |
|       |                | Triggers Th1 cytokines and interferon expression. |
|       |                | Increases expression of co-stimulatory molecules and integrins (Khan et al., 2009). |
| 3.    | Cinnamon       | Inhibits allergen specific immune responses. |
|       |                | Protects from systemic inflammation and lung injury by attenuating NLRP3 inflammasome activation (Sharma et al., 2016; Xu et al., 2019; Ose et al., 2020). |
| 4.    | Cardamom       | Has anti-microbial activity (Agnihotri and Wakode, 2010). |
|       |                | Exerts anti-inflammatory effect by inhibiting mediators such as COX2, TNF-α and IL-6 (Majdalawieh and Carr, 2010; Kandikattu et al., 2017). |
| 5.    | Holy Basil     | Exerts anti-inflammatory effects by modulating cellular and humoral immunity. |
|       |                | Increases percentages of T-helper cells and NK-cells (Mondal et al., 2011; Kamyab and Estherghian, 2013). |
| 6.    | Cumin          | Thymoquinone in cumin has immuno-modulatory and anti-inflammatory properties. Suppresses inflammation by downregulation of COX2, IL-6, TNF-α and NO production, and enhancement of IL-10 production. |
|       |                | Modulates cellular and humoral immunity and regulates Th1/Th2 immune response. Enhances NK cell mediated cytotoxicity (Majdalawieh and Fayyad, 2015; Gholamnezhad et al., 2016, 2019). |
| 7.    | Neem            | Has anti-inflammatory, antibacterial and antioxidant effects. |
|       |                | Attenuates release of pro-inflammatory cytokines such as TNF-α and IL-6, thus modulating immune response; inhibits MCP-1 (monocyte chemoattractant protein-1) expression and recruitment of inflammatory cells (Hao et al., 2014; Lee et al., 2017). |
| 8.    | Saffron        | Has anti-inflammatory, radical scavenging and immuno-modulatory properties (Bolhassani et al., 2014; Moshiri et al., 2015). |
| 9.    | Amlaki         | Has anti-inflammatory and immune-regulating activities. |
|       |                | Promotes NK cell function and Antibody-dependent cellular cytotoxicity (ADCC) (Yang and Liu, 2014). |
| 10.   | Brahmi         | Has immunomodulatory effects (Kao et al., 2017). |
|       |                | Mediates anti inflammatory effects by preventing the release of pro-inflammatory cytokines such as IL6 and TNF-α from microglial cells and the immune cells of the brain (Nemetchek et al., 2017). |
| 11.   | Moringa        | Activates CD8+ T cells, promotes IL-10, IL-2, IL-6 and TNF-α production (Coriolano et al., 2018). |
| 12.   | Liquorice Root (Yashthimadhu) | Glycyrrhizin, the active compound of the liquorice root, inhibits SARS-associated coronavirus replication (Cinati et al., 2003a). |
|       |                | Reduces virus uptake by host cells (especially in case of influenza virus) (Mousa, 2017). |
|       |                | Glycyrrhizin also stimulates IFN-γ production by T cells. |
|       |                | Exerts anti-inflammatory effects by inhibiting INOS, COX2, IL-1β, TNF-α, IL-5 and IL-6 or by blocking trans-activation of NF-κB (Kuang et al., 2018; Fouladi et al., 2019). |
| 13.   | Shatavari      | Modulates the Th1/Th2 balance; promotes IgG3 secretion and IL-12 production; and inhibits IL-6 production (Pise et al., 2015). |
| 14.   | Coriander      | Has anti-inflammatory activity and boosts immunity (Li et al., 2016). |
| 15.   | Kapikacchu (Velvet Beans) | Modulates immune mediators such as NF-κB, IL-6, IFN-γ, TNF-α, IL-1β, INOS and IL-2 in the central nervous system (Rai et al., 2017). |
|       |                | Boosts the innate immune response (Sayad Musthafa et al., 2018). |
| 16.   | Ajwain         | Acts as an anti-inflammatory agent and exerts bronchodilatory effect (Boskabady et al., 2005, 2007; Bairwa et al., 2012). |
| 17.   | Manjishtha     | Serves as potential anti-inflammatory agent and immune modulator. |
|       |                | Increases functions of the lymphatic system (Lentini et al., 2020). |
| 18.   | Bibhitaki      | Boosts immunity (Shen et al., 2018). |
| 19.   | Guduchi, Giloy (Tinospora) | Serves as anti-oxidant and anti-inflammatory agent. |
|       |                | Regulates NF-κB basal signaling and production of pro-inflammatory mediators (Drama et al., 2017; Haque et al., 2017). |
|       |                | Possesses anti-inflammatory and wound healing properties (Ratha and Joshi, 2013). |
| 20.   | Haritaki       | Source of chloroquine, a common anti-malarial drug; exerts an effect on SAR CoV-2 by immune modulation and blockage of viral entry (Lentini et al., 2020). |
| 21.   | Cinchona Bark  | Suppresses the immune response (Darzi et al., 2018). |
|       |                | Regulates Th17 and Treg immune response (Zhang et al., 2018). |
| 22.   | Shatapushpa (Fennel) | Reduces pro-inflammatory cytokines like TNF-α, IL-1β, IL-5, IL-8, IL-10, IL-12, IL-13, IL-17, IFN-γ, IL-18, VEGF, IL-6 and RANKL by preventing NF-κB activation (Peterson et al., 2017). |
may have huge implication in clinical practice for improving the detection efficiency while alleviating the radiologist's workload (Dong et al., 2020; Shi et al., 2020). COVID-19 lesions in CT scans have a wide range of presentation in terms of appearance, size, and location in lungs, so, developing a system using either classical image processing approaches or conventional machine learning techniques relying on handcrafted features, is a challenging task. Recently, artificial intelligence (AI) has shown promise. It warrants better safety, higher accuracy and efficacy in imaging compared to the traditional, laborious imaging workflows. Alongside pioneering the basic clinical research, AI have enormous application in recent COVID-19 scenario which include provision for well allocated imaging platform, segmentation of infected and unaffected regions of lungs, clinical evaluation and diagnosis (Wang J. et al., 2020; Wang X. et al., 2020).

Role of deep learning

Deep learning technology which lies central to current concept of Artificial Intelligence has been effective in automated detection of lung diseases with high diagnostic accuracy. However, there are challenges when developing AI-empowered deep learning technologies for COVID-19 screening (Oh et al., 2020; Roy et al., 2020). Most of the deep learning based methods require annotating the lesions in CT volumes for effective disease detection. Annotating lesions and labeling of annotations are laborious and time consuming, and hence, are not desirable in times of rapid COVID-19 outbreak and simultaneous shortage of radiologists. Therefore, the major challenge of AI-empowered solutions is to determine the potential of a deep learning model based on patients’ chest CT volumes for automated and accurate COVID-19 diagnosis. It should require nominal expert annotation and should be easily trained, which will be extremely advantageous in developing AI solution rapidly for COVID-19 diagnosis. Due to the constraints of hardware resources, a major challenge is to educate a deep learning model using volumetric CT scans. Another problem is the inter-class similarity and variation across pneumonia lesions. Finally, the lung CT scan images from patients with pneumonia harbor large portions of non-lesion regions, which exhibit wide range of complex tissue level variations. These non-lesion regions often exert a negative impact on the overall performance of AI-based solutions.

Mobile Applications and Social Distancing Strategies

Aarogya Setu has been developed as a digital mobile COVID-19 tracking application, by the National Informatics Centre under the initiative of the Ministry of Electronics and Information Technology, Govt. of India, for effective awareness, management and mitigation of COVID-19 (Kodali et al., 2020). The Delhi Government has also launched the Delhi Corona app to create public awareness regarding availability of hospital facilities for COVID-19 treatment and also for complaint redressal regarding refusal to admit COVID-19 patients by hospitals with available facilities (retrieved on June 23, 2020). Apart from these mobile applications, the Govt. of India has promoted strict social distancing to contain spread of COVID-19 amongst the Indian population (Paital et al., 2020).

DISCUSSION

The COVID-19 health crisis has created a stir in the whole world including in India. There has been a global endeavor in terms of disease diagnosis, drug repurposing and vaccine development...
to combat this pandemic. In addition to actively participating in these efforts to improve therapeutics and vaccine development against SARS-CoV-2; the Government of India has taken several initiatives and measures to further contain the disease. The total numbers of active cases in India reached a peak in the month of September, 2020 and have reduced subsequently. Although there have been 148,774 deaths in India till December 30, 2020; the recovery rate of COVID-19 patients in India has increased to about 98.51% as on December 30, 2020 (see text footnote 8). COVID-19 infection may exert detrimental long term effects on organs such as lungs, liver, kidney, brain, and heart (Heneka et al., 2020). These may even last after recovery from COVID-19 and lead to life-threatening health issues53. Several clinical parameters such as blood levels of inflammatory mediators, neutrophil to lymphocyte ratio (NLR) and CT scan severity score have been evaluated for highlighting disease progression and the risk for development of post recovery complications such as pulmonary fibrosis, ARDS, neurological disorder or even multi-organ failure (Feng et al., 2020). Identification of blood borne easily detectable biomarkers could potentially stratify COVID-19 based on its severity and enable early prediction of progression to post recovery complications, thereby leading to better post COVID care and effective control of deaths due to such complications.

53 https://Www.Thehindu.Com/Sci-Tech/Health/the-Hindu-Explains-What-Are-the-Long-Term-Effects-of-Covid-19/Article32651206.Ece

REFERENCES

Agnihotri, S., and Wakode, S. (2010). Antimicrobial activity of essential oil and various extracts of fruits of greater cardamom. *Indian J. Pharm. Sci.* 72, 657–659. doi: 10.4103/0250-474x.78542

Agrawal, D. (2020). Ventilator politics—the big picture. *Indian J. Neurotrauma* 17, 1–2.

Agrawal, U., Raju, R., and Udwadia, Z. F. (2020). Favipiravir: a new and emerging drug. *Indian J. Med. Res.* 172, 657–659. doi: 10.4103/ijmr.ijmr_1125_20

Alam, M., Aziz, A., and Alizadeh, M. (2014). Antiviral effects of *Carum copticum* in guinea pigs. *Therapie* 69, 503–507. doi: 10.1016/j.therapie.2007.007

Alam, M., Aziz, A., and Alizadeh, M. (2014). Saffron and natural carotenoids: biochemical activities and anti-tumor effects. *Biochim. Biophys. Acta* 1845, 20–30. doi: 10.1016/j.bbagrm.2013.11.001

Biswas, N. K., and Majumder, P. P. (2020). Analysis of RNA sequences of 3636 SARS-CoV-2 collected from 55 countries reveals selective sweep of one virus type. *Indian J. Med. Res.* 151, 450–458. doi: 10.4103/ijmr.ijmr_1125_20

Boskabady, M. H., Alizadeh, M., and Jahanbin, B. (2007). Bronchodilatory effect of *Carum copticum* in airways of asthmatic patients. *Therapie* 62, 23–29. doi: 10.2515/therapie.20070007

Boskabady, M. H., Jandaghi, P., Kiani, S., and Hasan zadeh, L. (2005). Antitussive effect of *Carum coticum* in guinea pigs. *J. Ethnopharmacol.* 97, 79–82. doi: 10.1016/j.ejep.2004.10.016

Burkard, C., Verheije, M. H., Haagmans, B. L., Van Kuppeveld, F. J., Rottier, P. J., Bosch, B. J., et al. (2015). ATP1A1-mediated Src signaling inhibits coronavirus entry into host cells. *J. Virol.* 89, 4434–4448. doi: 10.1128/jvi.03274-14

Chan, J. F., Chan, K. H., Kao, R. Y., To, K. K., Zheng, B. J., Li, C. P., et al. (2013). Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. *J. Infect.* 67, 606–616. doi: 10.1016/j.jinf.2013.09.029

Chan, J. F., Yao, Y., Yeung, M. L., Deng, W., Bao, L., Jia, L., et al. (2015). Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. *J. Infect. Dis.* 212, 1904–1913. doi: 10.1093/infdis/jiv392

**AUTHOR CONTRIBUTIONS**

All the authors reviewed the literature, wrote the review, edited, and approved the manuscript.

**FUNDING**

Research support and publication charges are funded by Bose Institute Intramural Fund.

**ACKNOWLEDGMENTS**

SM was grateful to the Department of Science and Technology, Govt. of India for the DST-INSPIRE Fellowship. MK was supported by the Council for Scientific and Industrial Research Emeritus Scientist Scheme (21(1088)/19/EMR-II). JB was supported by the J.C. Bose National Fellowship (SB/52/JCB-049/2016).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2021.637362/full#supplementary-material
Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A., and Einav, S. (2020). A
Dong, D., Tang, Z., Wang, S., Hui, H., Gong, L., Lu, Y., et al. (2020). The role of
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., et al. (2020). Effectiveness of
Choudhary, R., and Sharma, A. K. (2020). Potential use of hydroxychloroquine,
Chen, I. Y., Moriyama, M., Chang, M. F., and Ichinohe, T. (2019). Severe
Coriolano, M. C., De Santana Brito, J., De Siqueira Patriota, L. L., De Araujo Soares,
Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H., and Doerr, H. W.
Duncan, J. S., and Ayache, N. (2020). Clinical and experimental effects of Nigella
Forni, G., Agostini, F., Battistoni, V., Gennari, L., Marzaro, F., et al. (2018). The activity
Darzi, S. E., Khazraei, S. P., and Amirghofran, Z. (2018). The immunoinhibitory
de Wilde, A. H., Jochmans, D., Posthuma, C. C., Zevenhoven-Dobbe, J. C., Van
Duncan, J. S., and Ayache, N. (2000). Medical image analysis: progress over two
days and the challenges ahead. IEEE Trans. Pattern Anal. Machine Intell. 22, 85–106. doi: 10.1109/34.824822
Feinmann, J. (2020). PPE: what now for the global supply chain? BMJ 369:m1910. doi: 10.1136/bmj.m1910
Feng, L., Zhai, Y. Y., Xu, J., Yao, W. F., Cao, Y. D., Cheng, F. F., et al. (2019). A
Furuta, Y., Gowen, B. B., Takahashi, K., Shiraki, K., Smeeg, D. F., and Barnard, D. L.
Fernandez-Albors, R., McFadden, G. I., and Maramorosch, K. (2006). Antiviral activities
Fazekas, E., Cser, L., Marosi, C., Dian, X., Zander, T., et al. (2020). A SARS-CoV-2 protein interaction map reveals targets for drug
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belji-Rammerstorfer,
Fouad, Z., Khayat, M., El-Sayed, T., and Elkordy, R. (2015). The anti-inflammatory
Feinberg, J., Popov, S., Duan, G., Zhang, W., Wang, Y., et al. (2020). The infection
Fei, Z., Zhang, R., Wang, B., Wang, L., Xiao, S., et al. (2020). A SARS-CoV-2 protein interaction map reveals targets for drug
Fei, Z., Zhang, R., Wang, B., Wang, L., Xiao, S., et al. (2020). A SARS-CoV-2 protein interaction map reveals targets for drug
Fei, Z., Zhang, R., Wang, B., Wang, L., Xiao, S., et al. (2020). A SARS-CoV-2 protein interaction map reveals targets for drug
Fei, Z., Zhang, R., Wang, B., Wang, L., Xiao, S., et al. (2020). A SARS-CoV-2 protein interaction map reveals targets for drug
Fei, Z., Zhang, R., Wang, B., Wang, L., Xiao, S., et al. (2020). A SARS-CoV-2 protein interaction map reveals targets for drug
Fei, Z., Zhang, R., Wang, B., Wang, L., Xiao, S., et al. (2020). A SARS-CoV-2 protein interaction map reveals targets for drug
Fei, Z., Zhang, R., Wang, B., Wang, L., Xiao, S., et al. (2020). A SARS-CoV-2 protein interaction map reveals targets for drug
Fei, Z., Zhang, R., Wang, B., Wang, L., Xiao, S., et al. (2020). A SARS-CoV-2 protein interaction map reveals targets for drug
Lelli, D., Sahbekar, A., Johnston, T. P., and Pedone, C. (2017). Curcumin use in pulmonary diseases: state of the art and future perspectives. Pharmacol. Res. 115, 133–148. doi: 10.1016/j.phrs.2016.11.017

Lentini, G., Cavalluzzi, M. M., and Habtemariam, S. (2020). COVID-19, chloroquine repurposing, and cardiac safety concern: chirality might help. Molecules 25:1834. doi: 10.3390/molecules25081834

Li, L., Qin, L., Xu, Z., Yin, Y., Wang, X., Kong, B., et al. (2020). Using artificial intelligence to detect COVID-19 and community-acquired pneumonia based on pulmonary CT: evaluation of the diagnostic accuracy. Radiology 296, E65–E71.

Li, Y., Yao, J., Han, C., Yang, J., Chaudhry, M. T., Wang, S., et al. (2016). Quecetin, inflammation and immunity. Nutrients 8:167. doi: 10.3390/nu8010367

Liao, M., Liu, Y., Yuan, J., Wen, Y., Xu, G., Zhao, J., et al. (2020). Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med. 26, 842–844. doi: 10.1038/s41591-020-0961-9

Liu, L., Wei, Q., Lin, Q., Fang, J., Wang, H., Kwok, H., et al. (2019). Anti-spika IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 4:e123158.

Lotfi, M., and Rezaei, N. (2020). CRISPR/Cas13: a potential therapeutic option of COVID-19. Biomed. Pharmacother. 131:110738. doi: 10.1016/j.biopha.2020.110738

Luo, P., Liu, Y., Qiu, L., Liu, X., Liu, D., and Li, J. (2020). Tocilizumab treatment in COVID-19: a single center experience. J. Med. Virol. 92, 814–818. doi: 10.1002/jmv.25801

Lyns, S. M., Harrison, M. A., and Law, S. E. (2011). Electrostatic application of antimicrobial sprays to sanitize food handling and processing surfaces for enhanced food safety. J. Phys. 301:012014. doi: 10.1088/1742-6596/301/1/012014

Magro, C., Mulvey, J. J., Berlin, D., Nuovo, G., Salvatore, S., Harp, J., et al. (2020). Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl. Res. 220, 1–13. doi: 10.1016/j.trsl.2020.04.007

Majdalawieh, A. F., and Carr, R. I. (2010). In vitro investigation of the potential immunomodulatory and anti-cancer activities of black pepper (Piper nigrum) and cardamom (Elettaria cardamomum). J. Med. Food 13, 371–381. doi: 10.1089/jmf.2009.1131

Majdalawieh, A. F., and Fayyad, M. W. (2015). Immunomodulatory and anti-inflammatory action of Nigella sativa and thymoquinone: a comprehensive review. Int. Immunopharmacol. 28, 295–304. doi: 10.1016/j.intimp.2015.06.023

Maij, A. K., Pandit, S., Banerji, P., and Banerjee, D. (2014). Psoraria tuberosa: a review on its phytochemical and therapeutic potential. Nat. Prod. Res. 28, 2111–2127. doi: 10.1080/17426596.2014.928291

Mani, K. A., and Kuttan, G. (2009). Immunomodulatory activities of Punarnavine, an alkaloid from Boerhavia diffusa. Immunopharmacol. Immunotoxicol. 31, 377–387. doi: 10.1080/08923970802702036

McBride, R., and Fielding, B. C. (2012). The role of severe acute respiratory syndrome (SARS)-coronavirus accessory proteins in virus pathogenesis. Viruses 4, 2902–2923. doi: 10.3390/v4112048

Mehta, P., Mcauley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., Manson, J. J., et al. (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033–1034. doi: 10.1016/s0140-6736(20)30628-0

Michot, J. M., Albiges, L., Chaput, N., Saada, V., Pommeret, F., Griscelli, F., et al. (2020). Tocilizumab, an anti–IL-6 receptor antibody, to treat COVID-19 related respiratory failure: a case report. Ann. Oncol. 31, 961–964. doi: 10.1093/annonc/mdaa020

Mishra, S. A., Aeri, V., Gaur, P. K., and Jachak, S. M. (2014). Phytochemical, therapeutic, and ethnopharmacological overview for a traditionally important herb: Boerhavia diffusa Linn. Biomed. Res. Int. 2014:808302.

Mishra, S., Mohapatra, A., Kumar, R., Singh, A., Bhadoria, A. S., and Kant, R. (2014). Phytochemical, therapeutic, and ethnopharmacological overview for a traditionally important herb: Boerhavia diffusa Linn. Biomed. Res. Int. 2014:808302.
Singh, A. K., and Misra, A. (2020). Impact of COVID-19 and comorbidities on health and economics: focus on developing countries and India. *Diabetes Metab. Syndr.* 14, 1625–1630. doi: 10.1016/j.dsx.2020.08.032

Sivasankarapillai, V. S., Pillai, A. M., Rahdar, A., Sobha, A. P., Das, S. S., Mitropoulos, A. C., et al. (2020). On facing the SARS-CoV-2 (COVID-19) with combination of nanomaterials and medicine: possible strategies and first challenges. *Nanomaterials (Basel)* 10:852. doi: 10.3390/nano10050852

Sluimer, I., Schilham, A., Prokop, M., and Van Ginneken, B. (2006). Computer analysis of computed tomography scans of the lung: a survey. *IEEE Trans. Med. Imaging* 25, 385–405. doi: 10.1109/tmi.2005.862753

Spinelli, F. R., Conti, F., and Gadina, M. (2020). HijAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19. *Sci. Immunol.* 5:eabc5367. doi: 10.1126/sciimmunol.abc5367

Sra, H. K., Sandhu, A., and Singh, M. (2020). Use of Face Masks in COVID-19. *Frontiers in Genetics* | www.frontiersin.org 21

Wang, C., Liu, Z., Chen, Z., Huang, X., Xu, M., He, T., et al. (2020). Accessory proteins Sb and Sf of severe acute respiratory syndrome coronavirus suppress the interferon signaling pathway by mediating ubiquitin-dependent rapid degradation of interferon regulatory factor 3. *Virology* 515, 165–175. doi: 10.1016/j.virol.2017.12.028

Wong, S. K., Li, W., Moore, M. J., Choe, H., and Farzan, M. (2004). A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. *J. Biol. Chem.* 279, 3197–3201. doi: 10.1074/jbc.c030520200

Xia, S., Zhang, Y., Wang, Y., Wang, H., Yang, Y., Gao, G. F., et al. (2021). Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. *Lancet Infect. Dis.* 21, 39–51. doi: 10.1016/s1473-3099(20)30831-8

Xu, F., Sang, W., Li, L., He, X., Wang, F., Wen, T., et al. (2019). Protective effects of ethyl acetate extracts of *Rutus cinnamomum* on systemic inflammation and lung injury in endotoxin-poisoned mice. *Drug Chem. Toxicol.* 42, 309–316. doi: 10.1080/01484054.2018.1509987

Yadav, P. D., Potdar, V. A., Choudhary, M. L., Nyayanit, D. A., Agrawal, M., Jadhav, S. M., et al. (2020). Full-genome sequences of the first two SARS-CoV-2 viruses from India. *Indian J. Med. Res.* 151, 200–209.

Yamamoto, M., Matsuyama, S., Li, X., Takeda, M., Kawaguchi, Y., Inoue, J. I., et al. (2016). Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus *S* protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay. *Antimicrob. Agents Chemother.* 60, 6532–6539. doi: 10.1128/aac0143-16

Yang, B., and Liu, P. (2014). Composition and biological activities of hydrolyzable tannins of fruits of *Phyllanthus emblica*. *J. Agric. Food Chem.* 62, 529–541. doi: 10.1021/jf400740k

Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., et al. (2020). In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Clin. Infect. Dis.* 71, 732–739. doi: 10.1093/cid/ciaa237

Ye, Q., Wang, B., and Mao, J. (2020). The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19. *J. Infect.* 80, 607–613. doi: 10.1016/j.jinf.2020.03.037

Yin, C. (2020). Genotyping coronavirus SARS-CoV-2: methods and implications. *Genomics* 112, 3588–3596. doi: 10.1016/j.ygeno.2020.04.016

Zeng, Q., Ye, Z. J., Gao, J. J., Li, G. M., Li, S. H., Zhang, G. F., et al. (2020). Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. *J. Infect. Dis.* 222, 38–43. doi: 10.1093/cid/ciaa228

Zhang, B., Zhou, X., Qu, Y., Song, Y., Feng, F., Feng, J., et al. (2020). Clinical characteristics of 82 cases of death from COVID-19. *PLoS One* 15:e0235458. doi: 10.1371/journal.pone.0235458

Zhang, H., Penninger, J. M., Li, Y., Zhang, N., and Slutsky, A. S. (2020). Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Med.* 46, 586–590. doi: 10.1007/s00134-020-05985-9

Zhang, S., Chen, X., Devshilt, I., Yun, Q., Huang, C., An, L., et al. (2018). Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. *Nat. Sci. Rev.* 7, 998–1002. doi: 10.1093/nsr/nwaa041

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Majumdar, Verma, Saha, Bhattacharyya, Maji, Surjit, Kundu, Basu and Saha. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.